Every inflammatory process, including that in the course of bronchial asthma may disturb the balance in blood coagulation and fibrinolysis system. The aim of the present study was to evaluate fibrinolysis in patients with bronchial asthma. The study group consisted of 41 patients with bronchial asthma, hitherto untreated (25 women, 16 men, at mean age 37.37±12.4 years) and 22 healthy adults (control group). In these subjects, the following parameters were established: euglobulin lysis time (ELT), the concentration of tissue plasminogen activator antigen (t-PA Ag), the concentration of urokinase plasminogen activator antigen (u-PA Ag), the activity of plasminogen activator inhibitor type 1 (PAI-1), the concentration of plasmin-antiplasmin complex (PAP) and fibrinogen/fibrin degradation products (FDP). It was found that patients with bronchial asthma had statistically significantly higher mean values of FDP (9.25±6.7 μg/ml vs. 5.0±5.9 μg/ml; p<0.001), ELT (123.5±42.7 min vs. 97.4±27.1 min; p<0.001), t-PA Ag (8.36±3.66 ng/ml vs. 5.5±3.71 ng/ml; p<0.01) and PAP complexes (250.3±95.8 ng/ml vs. 193.4±60.7 ng/ml; p<0.02). Mean u-PA Ag concentration in patients with bronchial asthma was significantly lower than in control group (0.24±0.16 ng/ml vs. 0.53±0.18 ng/ml; p<0.01). No statistically significant differences were observed as to PAI-1 activity between patients with bronchial asthma and healthy subjects. The results of the present study suggest that increased concentrations of t-PA Ag, PAP and FDP complexes are the evidence for greater activity of fibrinolysis system in subjects with bronchial asthma.
展开▼
机译：每个炎症过程，包括支气管哮喘过程中的炎症过程，都可能破坏血液凝固和纤溶系统的平衡。本研究的目的是评估支气管哮喘患者的纤维蛋白溶解。研究组包括41例迄今未接受治疗的支气管哮喘患者（25名女性，16名男性，平均年龄37.37±12.4岁）和22名健康成人（对照组）。在这些受试者中，建立了以下参数：球蛋白溶解时间（ELT），组织纤溶酶原激活物抗原（t-PA Ag）的浓度，尿激酶纤溶酶原激活物抗原（u-PA Ag）的浓度，纤溶酶原激活物的活性1型抑制剂（PAI-1），纤溶酶-抗纤溶酶复合物（PAP）和纤维蛋白原/纤维蛋白降解产物（FDP）的浓度。发现支气管哮喘患者的FDP平均值（9.25±6.7μg/ ml vs. 5.0±5.9μg/ ml; p <0.001），ELT（123.5±42.7 min vs. 97.4±27.1 min; P <0.001）均具有统计学上显着较高的平均值。 p <0.001），t-PA Ag（8.36±3.66 ng / ml vs. 5.5±3.71 ng / ml; p <0.01）和PAP复合物（250.3±95.8 ng / ml vs. 193.4±60.7 ng / ml; p < 0.02）。支气管哮喘患者的u-PA Ag平均浓度显着低于对照组（0.24±0.16 ng / ml与0.53±0.18 ng / ml; p <0.01）。支气管哮喘患者与健康受试者之间的PAI-1活性未观察到统计学上的显着差异。本研究的结果表明，t-PA Ag，PAP和FDP复合物浓度增加是支气管哮喘患者纤溶系统活性增强的证据。
展开▼
